| Size | Price | |
|---|---|---|
| 50mg | ||
| Other Sizes |
| Targets |
PSAR18-COOH does not have a defined pharmacological target, as it is a polymer derivative used for drug and diagnostic delivery systems. Its function is to serve as a highly hydrophilic, biodegradable, non-immunogenic, and water-soluble polymer carrier. As a delivery system component, it is designed to improve the solubility, stability, and targeting of therapeutic or diagnostic agents without specific biological target engagement.
|
|---|---|
| ln Vitro |
In vitro activity of PSAR18-COOH is related to its function as a polymer carrier for drug and diagnostic delivery systems. Its highly hydrophilic and water-soluble properties make it suitable for formulating poorly soluble compounds. The polymer is biodegradable and non-immunogenic, which are desirable properties for biomedical applications. Detailed in vitro activity data are not applicable as the compound is a polymer carrier rather than a pharmacologically active agent.
|
| ln Vivo |
In vivo activity of PSAR18-COOH is related to its function as a delivery system component for drugs or diagnostics. Its biodegradability, non-immunogenicity, and water solubility make it suitable for in vivo applications. The polymer can be used to improve the pharmacokinetics and biodistribution of therapeutic or diagnostic agents. Detailed in vivo efficacy data depend on the specific payload being delivered and are not available for the carrier itself.
|
| Enzyme Assay |
The in vitro enzyme/receptor binding assay for PSAR18-COOH is not applicable, as the compound is a polymer carrier rather than a pharmacologically active agent. However, characterization assays may be performed to assess its physicochemical properties, including molecular weight determination, solubility testing, and degradation studies. Standard protocols include HPLC, mass spectrometry, and dynamic light scattering to evaluate polymer properties.
|
| Cell Assay |
In vitro cell-based assays for PSAR18-COOH are not directly applicable, as the compound is a polymer carrier rather than a pharmacologically active agent. However, cytotoxicity and cellular uptake studies may be performed using formulations containing PSAR18-COOH to evaluate the safety and efficacy of the delivery system. Cells are treated with polymer formulations, and cell viability is measured using standard assays. Uptake and intracellular distribution may be assessed using fluorescently labeled polymers.
|
| Animal Protocol |
In vivo animal studies for PSAR18-COOH are typically conducted in the context of drug or diagnostic delivery applications. Animals are administered formulations containing the polymer carrier with a therapeutic or diagnostic payload, and pharmacokinetics, biodistribution, and efficacy are evaluated. The polymer's biodegradability and non-immunogenicity are assessed. Standard protocols include monitoring of body weight, organ weights, and histological examination of tissues.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of PSAR18-COOH include a molecular weight of 1339.45 g/mol and formula C56H94N18O20. Solubility includes DMSO at ≥100 mg/mL (74.66 mM). Storage recommendations include -20°C, sealed storage away from moisture and light, under nitrogen. Stock solution can be stored at -80°C for 6 months or -20°C for 1 month. As a polymer carrier, detailed pharmacokinetic parameters depend on the payload being delivered.
|
| Toxicity/Toxicokinetics |
Toxicity information for PSAR18-COOH is limited. As a biodegradable, non-immunogenic polymer, it is expected to have low toxicity. Standard safety precautions for handling research chemicals should be followed. The compound is designated for research use only and is not for human therapeutic applications. No detailed toxicity data are available from the search results.
|
| References | |
| Additional Infomation |
PSAR18-COOH is a derivative of PSAR, a highly hydrophilic, biodegradable, non-immunogenic, and water-soluble polymer used in drug and diagnostic delivery systems. It has MW 1339.45 and formula C56H94N18O20. It is soluble in DMSO at ≥100 mg/mL. It is derived from patent WO2009064913A1. It is intended for research use only.
|
| Exact Mass |
1338.689
|
|---|---|
| CAS # |
2313534-26-6
|
| PubChem CID |
155633673
|
| Appearance |
White to off-white solid powder
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
20
|
| Rotatable Bond Count |
36
|
| Heavy Atom Count |
94
|
| Complexity |
2860
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC(=O)N(C)CC(=O)N(C)CC(=O)N(C)CC(=O)N(C)CC(=O)N(C)CC(=O)N(C)CC(=O)N(C)CC(=O)N(C)CC(=O)N(C)CC(=O)N(C)CC(=O)N(C)CC(=O)N(C)CC(=O)N(C)CC(=O)N(C)CC(=O)N(C)CC(=O)N(C)CC(=O)N(C)CC(=O)N(C)CC(=O)O
|
| InChi Key |
JIEODKKMWFZWII-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C56H94N18O20/c1-38(75)57(2)20-39(76)58(3)21-40(77)59(4)22-41(78)60(5)23-42(79)61(6)24-43(80)62(7)25-44(81)63(8)26-45(82)64(9)27-46(83)65(10)28-47(84)66(11)29-48(85)67(12)30-49(86)68(13)31-50(87)69(14)32-51(88)70(15)33-52(89)71(16)34-53(90)72(17)35-54(91)73(18)36-55(92)74(19)37-56(93)94/h20-37H2,1-19H3,(H,93,94)
|
| Chemical Name |
2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[acetyl(methyl)amino]acetyl]-methylamino]acetyl]-methylamino]acetyl]-methylamino]acetyl]-methylamino]acetyl]-methylamino]acetyl]-methylamino]acetyl]-methylamino]acetyl]-methylamino]acetyl]-methylamino]acetyl]-methylamino]acetyl]-methylamino]acetyl]-methylamino]acetyl]-methylamino]acetyl]-methylamino]acetyl]-methylamino]acetyl]-methylamino]acetyl]-methylamino]acetic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO :≥ 100 mg/mL (~74.66 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
